Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Celularity (CELU): Assessing the Path to the $1.50 Conversion Level

Celularity (CELU): Assessing the Path to the $1.50 Conversion Level

Key Takeaways

  • The central target of $1.50 is not an analyst consensus; it reflects the initial conversion price of the company's September 2026 recapitalization notes, a publicly documented technical milestone.
  • Celularity Inc. (CELU) last traded near $0.46, so reaching $1.50 would require a gain of roughly 225% — a very large move.
  • Analyst coverage is thin: one current price target ($6 from WBB Securities, set in September 2025) remains the only recent figure, and it is now more than a year old, so no meaningful multi-analyst consensus exists.
  • The strongest supporting factors are the completed recapitalization, regained Nasdaq compliance, a long-term manufacturing collaboration, and the out-licensing of its biomaterials business.
  • The biggest risks are a going-concern warning, declining revenue, negative cash flow, limited cash, and potential dilution from convertible notes and future raises.
  • For more context on this stock, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
  • You can also explore Trending AI Robots to see how AI-driven strategies track stocks like this one.

How the $1.50 Target Was Established

Celularity Inc. (CELU) is a clinical-stage regenerative and cellular medicine company, not an ETF. Because it has only a single recent, attributable analyst price target — WBB Securities (analyst Steve Brozak) set a $6 target when it upgraded the stock from Hold to Buy on September 9, 2025 — there is no meaningful multi-analyst average to calculate. Earlier targets from HC Wainwright, Morgan Stanley, Oppenheimer, Truist, and Alliance Global Partners date to 2021–2023 and are clearly stale. For context only, the lone current figure is $6; it is far above the market price and should not be read as a realistic near-term objective.

Given the lack of a credible analyst consensus, the $1.50 level used here comes from public discussion and a verifiable structural milestone: the initial conversion price of the notes issued in Celularity's September 2026 recapitalization. The notes carry a 10% interest rate, a 24-month maturity, and an initial conversion price of $1.50 per share. That level is frequently cited in market commentary as a reference point for the shares, and it sits comfortably more than 10% above the current price. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

As of mid-November 2026, Celularity shares traded near $0.46, within a 52-week range of roughly $0.42 to $2.55. Reaching $1.50 would require a move of about 225%, which is a very large percentage gain. The path is complicated by a sharp recent decline: the stock has fallen from around $1.26 in late October 2026, reflecting heavy volatility and thin liquidity typical of a penny stock.

Fundamentally, the company reported fiscal 2025 revenue of about $26.6 million, down roughly 51% from $54.2 million in 2024, alongside a net loss near $92 million. Cash on hand was reported around $0.6 million with total debt near $36 million, and management has acknowledged going-concern and financing risk. Reaching $1.50 would therefore likely require both a stabilization of operations toward the company's stated goal of positive operating cash flow by early 2027 and sustained investor confidence in its restructuring.

What Could Support a Move Toward the Target

Several verified developments could support a recovery. In October 2026 the company regained compliance with Nasdaq's periodic reporting requirements after filing overdue quarterly reports. A recapitalization completed a first closing in September 2026, raising over $10 million with up to $25 million contemplated, and management said monthly cash burn had fallen by more than $1 million. In August 2026 Celularity announced a manufacturing collaboration to produce Dezawa MuseCell, with the partner projecting more than $300 million in aggregate purchases over five years. It also out-licensed its biomaterials business for up to $30 million and eliminated roughly $13 million of liabilities. These steps address liquidity and reporting risks that have weighed on the stock. From what I see, these operational updates are worth monitoring closely.

What Could Prevent the Target From Being Reached

The obstacles are substantial. The company has posted declining revenue, persistent losses, negative operating cash flow, and a going-concern disclosure. Its cash balance is very small relative to its debt, and future capital raises or note conversions could dilute existing shareholders. Later closings of the recapitalization are not assured, and the stock's thin liquidity and wide bid-ask spreads amplify downside risk. The fact that the shares trade well below the $1.50 conversion price itself signals market skepticism about the recapitalization's terms.

Technical Levels and Market Structure

The shares sit near the lower end of their 52-week range, with the $0.42 area representing a recent low and potential support level. On the upside, the round-number $1.00 level and, notably, the $1.50 note-conversion price act as resistance references, while the 52-week high near $2.55 marks a more distant ceiling. The stock's multi-month downtrend and heavy recent selling suggest that any move toward $1.50 would first require reclaiming and holding above short-term resistance zones in the $0.60–$0.80 range.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a research horizon of roughly 12 months, but the lone WBB Securities figure is more than a year old and should be treated cautiously. Key items to watch include the filing of the quarter ended September 30, 2026, further closings of the recapitalization, progress toward the company's positive-operating-cash-flow goal for the first quarter of 2027, the manufacturing collaboration's execution, and any additional financing or note conversions. Earnings, cash-burn updates, and analyst coverage changes will be the most direct signals. I'm watching this closely as the next earnings update approaches.

Final Assessment

Whether Celularity (CELU) can reach $1.50 depends on a turnaround that has yet to be demonstrated. The target is a structural reference — the initial note conversion price — rather than a consensus of analysts, and the roughly 225% move required is very large. Support comes from the completed recapitalization, restored Nasdaq compliance, and new commercial arrangements, while going-concern risk, negative cash flow, and potential dilution remain the principal obstacles. Investors should weigh the thin, stale analyst coverage, the stock's sharp recent decline, and upcoming financial filings rather than treating $1.50 as a probable destination.

Exploring AI Daily Buy/Sell Signals

For traders seeking an additional lens on names like Celularity, AI Daily Buy/Sell Signals from Tickeron use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. I have found this approach helpful in my own review of volatile micro-cap names, providing a data-driven complement to fundamental research without replacing it.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CELU

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Momentum Indicator for CELU turns negative, indicating new downward trend

CELU saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 85 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

CELU moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CELU crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for CELU entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELU advanced for three days, in 213 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

CELU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.197) is normal, around the industry mean (3.596). P/E Ratio (-0.228) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1.244) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. CELU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -16%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a blank check company, which focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization

Industry Biotechnology

Industry
N/A
Address
170 Park Avenue
Phone
+1 908 768-2170
Employees
115
Web
https://www.celularity.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.